<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<rss xmlns:ev="http://purl.org/rss/1.0/modules/event/" version="2.0">
    
    <channel>
      <title>Novavax Perspectives and Insights</title>
      <link>https://www.novavax.com/perspectives-insights</link>
                      <item>
          <title>Behind the Pipeline: The Benefits of Matrix-M&#xAE;</title>
          <link>https://rdhawqgy.novavax.com/perspectives-insights/behind-pipeline-benefits-matrix-m</link>
          <description>Published on Spring 2026, Video featuring Karin L&#xF6;vgren Bengtsson, PhD, Chief Scientist, Adjuvant CMC, and Jenny Reimer, PhD, MBA, Senior Director CMC Strategy and PMO</description>
          <guid>https://rdhawqgy.novavax.com/perspectives-insights/behind-pipeline-benefits-matrix-m</guid>
        </item>
                <item>
          <title>R&amp;D Reflections from the Global Vaccine Stage</title>
          <link>https://rdhawqgy.novavax.com/perspectives-insights/rd-reflections-global-vaccine-stage</link>
          <description>Published on Winter 2025, By Ruxandra Draghia-Akli, MD, PhD, EVP, Head of Research &amp; Development </description>
          <guid>https://rdhawqgy.novavax.com/perspectives-insights/rd-reflections-global-vaccine-stage</guid>
        </item>
                <item>
          <title>Understanding Vaccine Terminology: Adjuvants, Protein-Based Nanoparticles and More</title>
          <link>https://rdhawqgy.novavax.com/perspectives-insights/understanding-vaccine-terminology-adjuvants-protein-based-nanoparticles-and</link>
          <description>Published on Fall 2025</description>
          <guid>https://rdhawqgy.novavax.com/perspectives-insights/understanding-vaccine-terminology-adjuvants-protein-based-nanoparticles-and</guid>
        </item>
                <item>
          <title>Behind the Pipeline: Our R&amp;D Strategy</title>
          <link>https://rdhawqgy.novavax.com/perspectives-insights/behind-pipeline-our-rd-strategy</link>
          <description>Published on Fall 2025, Video featuring Kumar Singh Saikatendu, SVP, Translational Medicine</description>
          <guid>https://rdhawqgy.novavax.com/perspectives-insights/behind-pipeline-our-rd-strategy</guid>
        </item>
                <item>
          <title>Where Intent Meets Impact: Bringing Corporate Values to Life</title>
          <link>https://rdhawqgy.novavax.com/perspectives-insights/where-intent-meets-impact-bringing-corporate-values-life</link>
          <description>Published on Fall 2025, By Ian Watkins, EVP, Chief Human Resources Officer</description>
          <guid>https://rdhawqgy.novavax.com/perspectives-insights/where-intent-meets-impact-bringing-corporate-values-life</guid>
        </item>
                  </channel>
  </rss>
